Presentation is loading. Please wait.

Presentation is loading. Please wait.

Craig W. Hendrix, MD Johns Hopkins University

Published byΜέντωρ Ζυγομαλάς Modified over 5 years ago

Similar presentations

Presentation on theme: "Craig W. Hendrix, MD Johns Hopkins University"— Presentation transcript:

1 Craig W. Hendrix, MD Johns Hopkins University
DREAM Program On Demand, Behaviorally-Congruent Rectal Microbicide Douche Craig W. Hendrix, MD Johns Hopkins University

2 Outline Rectal microbicide need & feasibility
Rectal microbicide history (tenofovir) DREAM Program Mouse & macaque development Human development Future Studies

3 Rectal Microbicide Feasibility
Oral PrEP not for everyone Product options improve adherence On demand oral TDF/FTC & vaginal PrEP works Rectal TFV gel high adherence Behaviorally-congruent formulations “piggy- back” onto commonly used sex products

4 Rectal Microbicide Development
Are rectal douches acceptable to those at risk? Can tenofovir be delivered safely by douche? Can douches provide protective concentrations? Can a rectal douche prevent HIV?

5 TFV Rectal Microbicide Development
Methods/Vehicle Development JHU “HIV” surrogate distribution Tissue pharmacology CDC/NIH Luminal PK-D imaging NIH PD Surrogates: Explant, BLT, NHP MDP 2/2b RF vehicle development MDP 1 Enema vehicle development Lube dosing feasibility Phase I Phase II Phase III Drug Product Development Vaginal Formulation (VF) 3,111 mOsm/kg TFV 1% Reduced Glycerin (RGVF) 836 mOsm/kg Rectal Formulation (RF) 479 mOsm/kg Douche Formulation (DF) Hypo-osmolar RMP-02/MTN-006 No Phase II Safety/AEs MTN-017 No Phase III Applicator (Safety) MTN-007 CHARM 01/02 Future RCT ? On Demand Lube Phase I-II ? TFV 10% RF Lube Safety/Accept Future RCT ? On Demand Douche Phase II ? TFV Douche Safety/Accept DREAM 01-03

6 DREAM Program Background Objective Process
Adherence & choice greatest PrEP needs On demand, behaviorally congruent product desired Douche behaviorally-congruent (80% RAI MSM) Objective Single dose TFV (prodrug) enema, 1 week protection Process Sequential mice, macaque, human evaluation Select best of 4 tenofovir-related drugs Optimize formulation

7 Grindr Survey 4,751 Took Grindr Survey (OCT-NOV 2017)
78% RAI last 3 months 80% douche before RAI 27% douche after RAI (independent of above) Likelihood of using a microbicide douche (currently douche) Likelihood of using a microbicide douche (currently do not douche) Top supportive of RM douching partner Alex Carballo-Dieguez & Rebecca Giguere (DREAM U19 Project 1)

8 Douche Vehicle Evaluation
MIP Coronal SPECT/CT ISO ISO & HYPO HYPER Toxicity Distribution Acceptability Leyva, et al. ARHR 2013 9 men, single dose of 3 different douches Hyperosmolar (Fleet), Iso-osmolar (Saline-like), hypo-osmolar (tap water) Luminal distribution, histology, acceptability favor iso- & hypo-osmolar

9 Speeding Tissue Absorption
Iso-osmolar Hypo-osmolar Iso Hypo Osmolarity Fluorescent particle distribution in mouse vagina 10’ post-dose Administered in isotonic (left) or hypotonic (right) fluid Hypo-osmolar best mucosal surface coverage Ensign, et al., Biomaterials 2013 & Sci Trans Med 2012

10 Mouse TFV Prodrug Comparison
Target Hypo-osmolar better for some TFV prodrugs Variability significant Target achieved by median of TFV & all prodrugs Ensign et al 2017 (in review); Xiao et al AAC 2017

11 Interspecies comparisons
Interspecies TFV-DP Comparisons Interspecies comparisons TFV-DP Target TFV-DP active form of tenofovir Hypo-osmolar best >5x increases in tissue TFV-DP in macaques Variability high (2 log10 range common) Target exceeded by median low & high doses Xiao et al AAC 2017

12 NHP Oral TDF v. TFV Douche PK
Plasma similar TFV with oral & rectal dosing Colon TFV-DP far higher with rectal dosing Controversy whether blood or tissue is more important Francois Villinger, University of Louisiana (Lafayette) CROI LB 2018

13 Macaque Virus Challenge
Weekly rectal monkey HIV (SHIV) challenge Measure SHIV in plasma Hypo-Osmolar Iso-Osmolar Rectal hypo-osmolar dosing Highly protective Superior to oral dosing Francois Villinger, University of Louisiana (Lafayette) CROI LB 2018

14 Clinical Study: DREAM-01
Design: Phase I, single ascending dose study Goal: Find dose safely achieving colon TFV-DP target Objectives: Safety, drug concentration, & acceptability Products (125 mL): A: TFV 1.76 mg/mL (normal saline) B: TFV 5.28 mg/mL (normal saline) C: TFV 5.28 mg/mL (half-normal saline) Subjects: 18 MSM receive all 3 products sequentially

15 Epithelial Denudation Lamina propria Hemorrhage
Safety AE: None > Grade 2 Product Time Overall Grade (0-5) Epithelial Denudation (0-3) Lamina propria Hemorrhage Baseline Pre-Dose 0.5 1.0 0.0 Product A 1 or 3 hrs 24 hrs 3.0 72 hrs Product B Histology: No Change from Baseline Total Product A Product B Participants who experienced an AE Grade 1 3 1 Grade 2 2 6 5 Total # of AE’s Reported 9 8 12 10 Product C not shown No adverse events due to douche product No colon tissue damage

16 Colonic Luminal Distribution
Desired Distribution in Colon Distribution variable 1 hr Product A Product B J001 J002 J003 J004

17 Human vs. Macaque Blood TFV
Human Plasma TFV Macaque Plasma TFV Macaque greater than human blood exposure Human rectal douche greater than vaginal TFV gel

18 Human > Macaque Colon TFV-DP
Douche B Douche C Human

19 DREAM-02: Douche & Semen/HIV Distribution
“Microbicide”(111In-DTPA) “HIV” (99mTc-SC) in Ejaculate Does douching after sex worsen HIV distribution? Compare sequences – Douche then sex – Sex then douche Example of SPECT/CT Distribution of product (left) And HIV surrogate (right) Rectal TFV gel (0h), simulated sex/ejaculation (1h), SPECT/CT (2h) Amber bones, Color product or “HIV” Hiruy, et al. ARHR 2015

20 DREAM-03: Multiple Douche Impact
Do multiple douches increase tissue drug concentration? Do non-medicated douches reduce tissue concentration? DREAM-03 Design Sequence 1st douche 2nd douche 3rd douche A TFV B Half-Saline C

21 TFV Advanced Development
Pharmaceutics Sachet packaging In line hose attachment Mouse TFV nanoformulation douche TFV thermoreversible gelling douche Macaque PK & SHIV challenge w/ optimized nano/gelling form

22 Summary Grindr survey: behavioral congruence sound DREAM Pre-Clinical
Hypo-osmolar formulations increase tissue TFV-DP Douche better than oral in NHP SHIV challenge DREAM-01 Clinical No toxicity seen TFV-DP colon “target” exceeded by 2-3log10 in 1-3 hrs Plasma TFV below & colon TFV-DP above NHP Multiple dose & packaging studies planned RCTs needed to demonstrate HIV protection

23 Acknowledgements Study Volunteers
NIH/DAIDS IP/CP-HTM Program - Jim Turpin, Hans Spiegel, Cherlynn Mathias, Jeanna Piper, James Cummins, Anabel Lowry Johns Hopkins - Mark Marzinke, Namandje Bumpus, Edward Fuchs, Ethel Weld, Rahul Bakshi, Laura Ensign, Justin Hanes, Richard Cone University of Pittsburgh - Ian McGowan, Lisa Rohan, Ken Ho, Lin Wang, Cindy Jacobsen, Jarrett Engstrom, Rhonda Brand UCLA- Peter Anton, Julie Elliott, Terry Sanders Columbia - Alex Carballo-Dieguez, Rebecca Giguere University of Louisville (Fayette)- Francois Villinger, Xiao Peng Emory - Sanjeev Gumber Duke - David Katz UCSF - Rada Savic CONRAD- -Tim McCormack SAB -Jim Pickett, Tom Moench, Florian Hladik, Jose Romero

24 Thank You!

Download ppt "Craig W. Hendrix, MD Johns Hopkins University"

Similar presentations

Douche as Microbicide Vehicle: Safety, Pharmacokinetics, Acceptability of 3 Candidates Craig W. Hendrix, MD Johns Hopkins University NIH Grant IP/CP U19.

Douche as Microbicide Vehicle: Safety, Pharmacokinetics, Acceptability of 3 Candidates Craig W. Hendrix, MD Johns Hopkins University NIH Grant IP/CP U19.
Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention
Extracellular and Intracellular Tenofovir DF and Emtricitabine Exposure in Mucosal Tissue after a Single Dose of Fixed-Dose TDF/FTC: Implications for Pre-exposure.

Extracellular and Intracellular Tenofovir DF and Emtricitabine Exposure in Mucosal Tissue after a Single Dose of Fixed-Dose TDF/FTC: Implications for Pre-exposure.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Treatment and Cure Highlights Shireesha Dhanireddy Robert Harrington March 17, 2014 No financial.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER CROI 2015: Treatment and Cure Highlights Shireesha Dhanireddy Robert Harrington March 17, 2014 No financial.
Use of Antivirals in Prevention Oral and Topical Prophylaxis

Use of Antivirals in Prevention Oral and Topical Prophylaxis
The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.

The 4 th Decade of the HIV Epidemic: Midwest Regional Response September 17, 2013 with Jim Pickett, AFC/IRMA The Bottom Line on Rectal and Vaginal Microbicide.
Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.

Jim Pickett, IRMA/AFC GMHC – January 23, 2013 The Bottom Line on Rectal Microbicide Research.
Intermittent PrEP Opportunities and Challenges of Oral iPrEP Jean-Michel Molina Department of Infectious Diseases Saint-Louis Hospital, INSERM U941 University.

Intermittent PrEP Opportunities and Challenges of Oral iPrEP Jean-Michel Molina Department of Infectious Diseases Saint-Louis Hospital, INSERM U941 University.
Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.

Microbicide Research: A Promising HIV/AIDS Prevention Strategy for Women Roberta Black, Ph.D. Division of AIDS, National Institute of Allergy and Infectious.
Making Pharmacological Sense of the Successes and Failures Among PrEP Clinical Trials Craig Hendrix, MD Johns Hopkins University.

Making Pharmacological Sense of the Successes and Failures Among PrEP Clinical Trials Craig Hendrix, MD Johns Hopkins University.
Starting and Stopping PrEP: Lessons from Pharmacology David V. Glidden University of California at San Francisco IAS 2015, Vancouver 20 July 2015

Starting and Stopping PrEP: Lessons from Pharmacology David V. Glidden University of California at San Francisco IAS 2015, Vancouver 20 July 2015
DAIDS IPCP-HTM NIH/NIAID: 1 st IPCP on Rectal Microbicides Developments (2004-2011) Two Phase 1 Clinical Trials: RMP-01: Topical UC781 (single & 7-day.

DAIDS IPCP-HTM NIH/NIAID: 1 st IPCP on Rectal Microbicides Developments ( ) Two Phase 1 Clinical Trials: RMP-01: Topical UC781 (single & 7-day.
Www.global-campaign.org Rectal Microbicides: New Hope for Non-Condom Prevention of HIV and other STDs.

Rectal Microbicides: New Hope for Non-Condom Prevention of HIV and other STDs.
Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.

Microbicides for HIV Prevention Pamina M. Gorbach, Epidemiology & Infectious Diseases UCLA.
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel Ian McGowan, Craig Hoesley, Ross Cranston,

A Phase 1 Randomized, Double-Blind, Placebo-Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel Ian McGowan, Craig Hoesley, Ross Cranston,
State of Global Rectal Microbicide Research Ian McGowan MD PhD FRCP Magee-Womens Research Institute University of Pittsburgh.

State of Global Rectal Microbicide Research Ian McGowan MD PhD FRCP Magee-Womens Research Institute University of Pittsburgh.
An NIH IP/CP for Topical Microbicides The Evolving Design of Rectal Microbicide Safety Studies: a Perspective from Two Trials Peter Anton Center for HIV.

An NIH IP/CP for Topical Microbicides The Evolving Design of Rectal Microbicide Safety Studies: a Perspective from Two Trials Peter Anton Center for HIV.
MTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir Craig Hendrix, Alexandra Minnis, Vijayanand Guddera,

MTN-001 Phase 2 Adherence and Pharmacokinetic Study of Oral and Vaginal Preparations of Tenofovir Craig Hendrix, Alexandra Minnis, Vijayanand Guddera,
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.
Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Looking back, looking forward: what we know and don’t know about oral PrEP and tenofovir gel for preventing HIV in women Jared Baeten MD PhD Departments.

Similar presentations

Ads by Google